Key facts
- This page summarizes BAYER HEALTHCARE LLC's Form 4 filing for Azitra Inc (AZTR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Jul 2023, 17:51.
BAYER HEALTHCARE LLC - 21 Jun 2023 Form 4 Insider Report for Azitra Inc (AZTR)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- AZTR
- Reported as of
- 21 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jul 2023, 17:51:04 UTC
- Prior SEC filing
- 24 Jul 2023
- Next SEC filing
- 15 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- Bayer HealthCare LLC, By: /s/ Keith Abrams, Name: Keith Abrams, Title: Assistant Secretary
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
BAYER HEALTHCARE LLC filed Form 4 for Azitra Inc (AZTR) on 24 Jul 2023.
Change
- Previous filing in this sequence was filed on 24 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AZTR
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,307,401
- Change %
- Price
- Shares after
- 1,307,401
- Date
- 21 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AZTR
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -1,307,401
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,307,401
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date.
Footnote F2
The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.